Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Allarity Therapeutics, Inc.
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
June 27, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 25, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 20, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
May 14, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
May 07, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
May 06, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
May 02, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
April 17, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
April 04, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
March 27, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
March 25, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
March 08, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics to Present at Biomarkers 2024
February 28, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
December 12, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
December 05, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics to Present at Biomarkers Europe 2023
October 02, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
August 30, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
July 31, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
July 24, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
July 06, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
July 05, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
June 28, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
June 27, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
June 20, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
May 30, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
April 19, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
April 11, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
March 28, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
March 24, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.